Rigel Pharmaceuticals Quarterly Balance Sheet
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rigel Pharmaceuticals financial position
As of Jun 30, 2026, Rigel Pharmaceuticals reported total assets of $521.1 million, up 152.0% from a year earlier against total liabilities of $95.6 million. Shareholders' equity stood at $425.4 million, or 81.6% of assets. The company held $60.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 1.94, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Rigel Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 60.82M | 24.41M | 40.58M | 48.53M | 53.41M | 45.73M | 56.75M | 51.69M | 36.05M | 25.57M | 32.79M | 45.41M |
| Short-Term Investments | 34.51M | 122.27M | 114.38M | 88.61M | 54.97M | 31.37M | 20.57M | 9.42M | 13.05M | 23.98M | 24.15M | 16.94M |
| Receivables | 56.04M | 49.95M | 51.76M | 45.92M | 39.91M | 41.55M | 41.62M | 30.57M | 28.90M | 27.51M | 30.55M | 23.55M |
| Inventory | 14.37M | 11.65M | 11.51M | 13.30M | 10.42M | 4.66M | 6.00M | 4.78M | 8.06M | 6.58M | 5.52M | 6.11M |
| Total Current Assets | 185.53M | 234.03M | 240.17M | 214.93M | 175.39M | 146.56M | 135.10M | 106.47M | 94.72M | 92.49M | 99.27M | 95.02M |
| Property, Plant & Equipment | — | — | 30.00K | 54.00K | 57.00K | 76.00K | 92.00K | 99.00K | 115.00K | 140.00K | 165.00K | 190.00K |
| Intangible Assets | 93.88M | 24.16M | 24.75M | 25.34M | 25.92M | 26.51M | 27.10M | 27.69M | 28.27M | 28.86M | 13.88M | — |
| Total Assets | 521.07M | 504.61M | 513.59M | 242.53M | 206.74M | 175.97M | 163.98M | 139.42M | 128.41M | 126.52M | 117.22M | 115.32M |
| Accounts Payable | 4.01M | 4.49M | 7.19M | 3.85M | 7.29M | 3.95M | 3.34M | 3.81M | 6.13M | 9.28M | 7.14M | 8.00M |
| Total Current Liabilities | 95.59M | 89.49M | 99.24M | 94.40M | 86.64M | 66.63M | 63.30M | 54.31M | 58.65M | 73.20M | 53.27M | 48.27M |
| Long-Term Debt | — | 45.00M | 52.50M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M |
| Total Liabilities | 95.64M | 104.71M | 122.11M | 124.92M | 124.80M | 157.41M | 160.69M | 154.06M | 158.32M | 158.19M | 145.87M | 147.16M |
| Shareholders' Equity | 425.42M | 399.90M | 391.48M | 117.61M | 81.93M | 18.57M | 3.29M | -14.64M | -29.91M | -31.67M | -28.64M | -31.83M |
| Retained Earnings | -997.10M | -1.01B | -1.02B | -1.29B | -1.32B | -1.38B | -1.39B | -1.40B | -1.42B | -1.42B | -1.41B | -1.41B |
| Total Debt | — | 45.00M | 52.50M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M |
| Net Cash (Debt) | 95.33M | 101.68M | 102.45M | 77.14M | 48.38M | 17.10M | 17.32M | 1.11M | -10.90M | -10.45M | -3.07M | 2.35M |
| Shares Outstanding | — | — | 18.31M | — | — | — | 17.71M | — | — | — | 17.48M | — |
This table shows 12 quarterly periods of Rigel Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RIGL's reporting calendar. What is a balance sheet?